Dimensional Fund Advisors LP Has $6.73 Million Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Dimensional Fund Advisors LP lessened its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 17.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,112,910 shares of the medical instruments supplier’s stock after selling 242,478 shares during the quarter. Dimensional Fund Advisors LP owned 2.78% of AngioDynamics worth $6,733,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System increased its holdings in shares of AngioDynamics by 44.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 4,780 shares in the last quarter. Bayesian Capital Management LP acquired a new stake in AngioDynamics during the 1st quarter worth approximately $106,000. Concurrent Investment Advisors LLC lifted its stake in AngioDynamics by 152.2% in the second quarter. Concurrent Investment Advisors LLC now owns 29,503 shares of the medical instruments supplier’s stock valued at $178,000 after buying an additional 17,803 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in AngioDynamics by 9.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock valued at $199,000 after buying an additional 2,821 shares in the last quarter. Finally, Williams & Novak LLC boosted its holdings in shares of AngioDynamics by 94.5% in the second quarter. Williams & Novak LLC now owns 44,365 shares of the medical instruments supplier’s stock valued at $268,000 after buying an additional 21,550 shares during the period. 89.43% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO James C. Clemmer purchased 20,000 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was purchased at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the purchase, the chief executive officer now directly owns 681,582 shares in the company, valued at $4,109,939.46. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ANGO. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a report on Friday, October 4th. Canaccord Genuity Group cut their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th.

AngioDynamics Stock Down 3.6 %

NASDAQ ANGO opened at $5.88 on Wednesday. The firm’s 50 day moving average is $7.41 and its 200-day moving average is $6.65. The company has a market capitalization of $235.52 million, a PE ratio of -1.21 and a beta of 0.65. AngioDynamics, Inc. has a 12-month low of $5.26 and a 12-month high of $8.25.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The firm had revenue of $67.50 million for the quarter, compared to analyst estimates of $67.93 million. During the same period in the previous year, the business earned ($0.12) EPS. The company’s revenue was down 14.2% compared to the same quarter last year. As a group, sell-side analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.